| Autor: |
Shiseki M; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Ishii M; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Ohwashi M; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Wang YH; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Tanaka N; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Osanai S; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Yoshinaga K; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan., Mori N; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.; Department of Internal Medicine, Tokyo Women's Medical University Medical Center East 1-10, Tokyo, Japan., Tanaka J; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan. |
| Abstrakt: |
We investigated the clinical implications of pr eferentially expressed a ntigen in me lanoma (PRAME) expression in bone marrow cells of 116 patients with myelodysplastic syndromes (MDS). Quantitative RT-PCR was carried out to examine the PRAME expression level. High PRAME expression was observed in MDS patients classified into higher revised International Prognostic Scoring System (IPSS-R) risk categories (Very high and High) with a high bone marrow blast percentage (5% or higher). Kaplan-Meier analysis demonstrated that high PRAME expression is significantly associated with a poorer overall survival (OS) in MDS patients with a low bone marrow blast percentage (less than 5%) (log-rank test p = .0014) and those classified into lower IPSS-R risk categories (Very Low, Low, and Intermediate) (log-rank test, p = .0035). In contrast, there was no significant association between PRAME expression and OS in MDS patients with a high bone marrow blast percentage or those classified into higher IPSS-R risk categories. In addition, high PRAME expression was associated with early disease progression in MDS patients with a low bone marrow blast percentage. This study suggested PRAME expression to be a prognostic factor in MDS. |
